According to recent data discussed, what has been the impact of incorporating prophylactic tocilizumab prior to the first step-up bispecific dose on the incidence of CRS?
CRS incidence increased from 10–15% to 40–70%
CRS incidence decreased from 40–70% to 10–15%, mostly grade 1
CRS incidence remained unchanged but severity decreased